Source:http://linkedlifedata.com/resource/pubmed/id/16424864
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2006-2-23
|
pubmed:abstractText |
Among 11 JMML children, two had an abnormal karyotype, and nine had a normal karyotype at onset. In one patient with trisomy 8 and four patients with a normal karyotype, a new clone with an aberrant karyotype emerged 1-14 months after 6-mercaptopurine (6-MP) therapy as shown by G-banding analyses. Fluorescence in situ hybridization disclosed that an abnormal clone existed in approximately 3-6% of bone marrow cells at onset or before 6-MP therapy in all the four cases examined, and increased to approximately 12-90% during the treatment. In culture with granulocyte-macrophage colony-stimulating factor, cytogenetically abnormal clones that proliferated during 6-MP therapy possessed significantly less sensitivity to the antimetabolite, compared with cells that decreased in numbers after the therapy. A PTPN11 mutation was detected in all of granulocyte-macrophage colonies irrespective of karyotypic aberration in one patient, whereas approximately 80% of erythroid colonies and 20% of mixed colonies possessed neither a PTPN11 mutation nor chromosomal abnormalities. The appearance of chromosomal aberrations shown by G-banding during 6-MP therapy in some JMML cases may result, in part, from the growth of a 6-MP-refractory clone that already exists at onset. It is possible that treatment with 6-MP promotes progression of the disease.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/6-Mercaptopurine,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Intracellular Signaling Peptides...,
http://linkedlifedata.com/resource/pubmed/chemical/PTPN11 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Tyrosine Phosphatase...,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Tyrosine Phosphatases
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0887-6924
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
485-90
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16424864-6-Mercaptopurine,
pubmed-meshheading:16424864-Antineoplastic Agents,
pubmed-meshheading:16424864-Chromosome Aberrations,
pubmed-meshheading:16424864-Chromosome Banding,
pubmed-meshheading:16424864-Genes, ras,
pubmed-meshheading:16424864-Humans,
pubmed-meshheading:16424864-In Situ Hybridization, Fluorescence,
pubmed-meshheading:16424864-Intracellular Signaling Peptides and Proteins,
pubmed-meshheading:16424864-Leukemia, Myelomonocytic, Acute,
pubmed-meshheading:16424864-Mutation,
pubmed-meshheading:16424864-Protein Tyrosine Phosphatase, Non-Receptor Type 11,
pubmed-meshheading:16424864-Protein Tyrosine Phosphatases
|
pubmed:year |
2006
|
pubmed:articleTitle |
Chromosomal change during 6-mercaptopurine (6-MP) therapy in juvenile myelomonocytic leukemia: the growth of a 6-MP-refractory clone that already exists at onset.
|
pubmed:affiliation |
Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|